Announcements Trials
Browse Landscape

Status

No longer available 2Approved for marketing 2Available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 65Observational 28Expanded_access 5

Sponsor

Cancer Type

Endocrine 5CNS 5Head & Neck 1

Conditions

Glioblastoma 15Neuroblastoma 13Glioma 11Pheochromocytoma 7Neoplasms 6Recurrence 5Paraganglioma 5Pancreatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Brain Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Astrocytoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Typical Teratoid Rhabdoid Tumor 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1

Interventions

3-Iodobenzylguanidine 4fluorodopa F 18 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Expanded_access × Paraganglioma × CNS × Clear all
NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01590680 2023-02-28

Expanded Access Protocol Using 131I-MIBG

Jubilant DraxImage Inc.

Available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT02431715 2023-02-21

18F-FDOPA PET in Neuroendocrine Tumours

British Columbia Cancer Agency

No longer available
CNSEndocrineHead & Neck

Thyroid cancer, medullary, Carcinoid Tumor, Insulinoma, Neuroblastoma, Paraganglioma, Pheochromocytoma

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡